Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca

NCT00349466 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Keratoconjunctivitis Sicca

Interventions

DRUG: CF101
DRUG: Placebo

Sponsor

Can-Fite BioPharma